<i>CSRNP1</i> Promotes Apoptosis and Mitochondrial Dysfunction via ROS-Mediated JNK/p38 MAPK Pathway Activation in Hepatocellular Carcinoma
<i>CSRNP1</i> is a novel prognostic biomarker and tumor suppressor in HCC. It exerts anti-tumor effects by inducing oxidative stress and activating the JNK/p38 MAPK pathway in a ROS-dependent manner. These findings suggest that <i>CSRNP1</i> may serve as a potential therapeutic target in the management of HCC.
Authors
- Ke Lu (ORCID: https://orcid.org/0000-0002-1641-4748)
- Maoling Zhu (ORCID: https://orcid.org/0009-0006-1099-6624)
- Xuejing Lin
- Lei Chen (ORCID: https://orcid.org/0000-0002-9380-9559)
- Wenchao Wang (ORCID: https://orcid.org/0000-0001-7275-2648)
- Min Tang (ORCID: https://orcid.org/0000-0002-3381-7207)
- Huihui Shi (ORCID: https://orcid.org/0009-0003-8024-2674)
- Lei Huang (ORCID: https://orcid.org/0009-0002-6684-8912)
- Juan Huang (ORCID: https://orcid.org/0000-0003-2546-9166)
Institutions
- Yangpu Hospital of Tongji University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-10-09
- DOI
- https://doi.org/10.32604/or.2025.068737
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00